pentobarbital decreases levels of panobinostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inducers can reduce panobinostat levels by ~70% and lead to treatment failure.
pentobarbital will minimize the extent or outcome of levamlodipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
Induction of microsomal enzymes by this drug, may shorten the 50 percent-life of doxycycline for so long as two months immediately after barbiturate therapy discontinued; monitor scientific response to doxycycline carefully if both equally medications administered concurrently
pentobarbital will minimize the level or effect of diazepam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/watch.
pentobarbital will minimize the extent or effect of clozapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use warning/watch.
pentobarbital will reduce the extent or effect of tamoxifen by influencing hepatic enzyme CYP2C9/10 metabolism. Use warning/observe.
pentobarbital will reduce the level or impact of nilotinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/keep an eye on.
pentobarbital will decrease the level or influence of fludrocortisone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/check.
pentobarbital will lessen the extent or result of lumefantrine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with solid CYP3A4 inducers can result in lowered serum concentrations and loss of antimalarial efficacy
check Closely (2)pentobarbital will reduce the extent or effect of buprenorphine, prolonged-acting injection by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/observe intently. Patients who transfer to buprenorphine extensive-acting injection from transmucosal buprenorphine coadministered with CYP3A4 inducers needs to be monitored to make certain buprenorphine plasma ranges are adequate.
Barbiturates can induce hepatic microsomal enzymes leading to enhanced metabolism and lowered anticoagulant get more info response of oral anticoagulants (eg, warfarin, acenocoumarol, dicumarol, and phenprocoumon); patients stabilized on anticoagulant therapy may possibly involve dosage adjustments if barbiturates are extra to or withdrawn from their dosage program
pentobarbital will lessen the extent or outcome of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/keep track of.
pentobarbital will lower the level or influence of linagliptin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use warning/Monitor. Use of alternative treatment options is strongly suggested when linagliptin would be to be administered that has a CYP3A4 inducer
pentobarbital will decrease the extent or outcome of alosetron by impacting hepatic/intestinal enzyme CYP3A4 metabolism. minimal/Significance unfamiliar.